NEW HOPE, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its second quarter 2023 financial results and provided a business update. “We are excited about this […]
Financial
Milestone Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Corporate Update
MONTREAL and CHARLOTTE, N.C., Aug. 10, 2023 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the second quarter ended June 30, 2023, and provided a clinical and corporate update. “The remainder of 2023 represents a transformative time for the […]
Cadrenal Therapeutics Provides Second Quarter 2023 Corporate Update
PONTE VEDRA, Fla., Aug. 10, 2023 /PRNewswire/ — Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) to prevent heart attacks, strokes and deaths due to blood clots in patients with certain rare medical conditions, today provided a corporate update in connection with the […]
CorVista Health Welcomes Dr. Tim Attebery as New Board Member
WASHINGTON–(BUSINESS WIRE)–CorVista Health, Inc, a leading digital health company dedicated to improving cardiovascular disease diagnosis, is pleased to announce the election of Dr. Tim Attebery to its Board of Directors. “Our shareholders, along with the leadership team of CorVista Health, are thrilled to have Tim join our Board of Directors” […]
BioCardia Reports Second Quarter 2023 Business Highlights and Financial Results
SUNNYVALE, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the second quarter of 2023 and filed its quarterly report on Form 10-Q for the three and six months ended […]
Ionis reports second quarter 2023 financial results
CARLSBAD, Calif., Aug. 9, 2023 /PRNewswire/ — – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”), today reported financial results for the second quarter of 2023. Financial results are summarized below: Three months ended June 30, Six months ended June 30, 2023 2022 2023 2022 (amounts in millions) Total revenue $188 $134 $319 $276 […]
Shockwave Medical Reports Second Quarter 2023 Financial Results
SANTA CLARA, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended June 30, 2023. Recent Highlights Recognized revenue of $180.2 million for […]
Acutus Medical Reports Second Quarter 2023 Financial Results
CARLSBAD, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the second quarter of 2023. Recent Highlights: Second quarter revenue of $5.3 million grew […]
Nyra Medical names Lori Chmura as Chief Executive Officer
ATLANTA, Aug. 8, 2023 /PRNewswire/ — Nyra Medical, an innovative medical device company developing a next generation transcatheter mitral valve repair technology, announced the appointment of Lori Chmura as Chief Executive Officer and Board Director. Lori succeeds Dr Murali Padala, who founded the company and will assume the role of Chief Scientific Officer. Nyra […]
Avinger Announces Conversion of 12% of CRG Term Debt into Equity
REDWOOD CITY, CA / ACCESSWIRE / August 4, 2023 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today announced the conversion of approximately 12% of its existing debt with entities affiliated with CRG Partners III […]



